natgillin/translations-raw huggingface dataset:
Table 21 Paediatric CD Study Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission
Študija Crohnove bolezni pri pediatričnih bolnikih Prenehanje zdravljenja s kortikosteroidi ali imunomodulatorji in remisija fistule
You should not take Imraldi with medicines containing the active substances anakinra or abatacept due to increased risk of serious infection.
Zdravila Imraldi ne smete jemati z zdravili, ki vsebujejo učinkovini anakinro ali abatacept zaradi povečanega tveganja za resne okužbe.
Table 22 Proportion of Patientsa Achieving HiSCRb at Weeks 24 and 36 After Treatment Reassignment from Weekly Adalimumab at Week 12 Placebo (treatment withdrawal) N = 73
b v 24. in 36. tednu po spremembi zdravljenja na jemanje adalimumaba vsak teden v 12. tednu Placebo (ukinitev zdravljenja)
Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (See Table 29).
Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali adalimumab, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 29).
The recommended Imraldi induction dose regimen for adult patients with moderately to severely active Crohn's disease is 80 mg at week 0 followed by 40 mg at week 2.
Priporočena shema odmerjanja zdravila Imraldi med indukcijo je pri odraslih bolnikih z zmerno do hudo aktivno Crohnovo boleznijo 80 mg 0. teden in nato 40 mg 2. teden.
During the controlled portions of pivotal adalimumab trials in adults of at least 12 weeks in duration in patients with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis, and uveitis, malignancies, other than lymphoma and nonmelanoma skin cancer, were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) per 1,000 patient-years among 5,291 adalimumab treated patients versus a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control patients (median duration of treatment was 4.0 months for adalimumab and 3.8 months for control-treated patients).
V kontroliranih delih preskušanj, ki podpirajo vlogo za pridobitev dovoljenja za promet adalimumaba pri odraslih, ki so trajala vsaj 12 tednov, pri bolnikih z zmerno do hudo aktivnim revmatoidnim artritisom, ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za AS, psoriatičnim artritisom, psoriazo, Crohnovo boleznijo, ulceroznim kolitisom in uveitisom so malignome (razen limfoma in nemelanomskega kožnega raka) opažali z deležem (95-% interval zaupanja) 6,8 (4,4; 10,5) na 1.000 bolnikov-let med 5.291 bolniki, ki so dobivali adalimumab, in 6,3 (3,4; 11,8) na 1.000 bolnikov-let med 3.444 kontrolnimi bolniki (pri prvih je zdravljenje mediano trajalo 4,0 meseca in pri drugih 3,8 meseca).
Tell your doctor immediately if you get symptoms like changes in your vision, weakness in your arms or legs or numbness or tingling in any part of your body.
Zdravniku takoj povejte, če dobite simptome, kot so spremembe vida, šibkost rok ali nog ali pa odrevenelost ali mravljinčenje v katerem koli delu telesa.
Imraldi is injected under the skin (subcutaneous use).
Zdravilo Imraldi se injicira pod kožo (subkutana uporaba).
Serious infections, including sepsis, due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or other opportunistic infections such as listeriosis, legionellosis and pneumocystis have been reported in patients receiving adalimumab.
Pri bolnikih, ki so dobivali adalimumab, so bile opisane resne okužbe, vključno s sepso, zaradi bakterijskih, mikobakterijskih, invazivnih glivičnih, parazitskih, virusnih in drugih oportunističnih okužb, npr. listerioza, legioneloza in pnevmocistična okužba.
Hypokalaemia, uric acid increased, blood sodium abnormal, hypocalcaemia, hyperglycaemia, hypophosphatemia, dehydration
nenormalni nivo natrija v krvi, hipokalciemija, hiperglikemija, hipofosfatemija, dehidracija
Across all treatment groups, the mean baseline PASI score was 19.7 and the baseline PGA score ranged from “mild” (<1%) to “moderate” (48%) to “severe” (46%) to “very severe” (6%).
V vseh terapevtskih skupinah je bila povprečna izhodiščna ocena PASI 19,7, izhodiščna PGA pa je segala od "blage" (< 1 %), "zmerne" (48 %) in "hude" (46 %) do "zelo hude" (6 %).
This risk may increase if your lung function is impaired.
Tveganje je lahko večje, če imate okvarjeno delovanje pljuč.
• DO NOT inject in an area where the skin is sore, bruised, scarred, scaly, or has red patches.
• NE INJICIRAJTE v kožo, ki je boleča ali so na njej modrice, brazgotine, luske ali rdeče lise.
At week 12, a significantly higher proportion of patients treated with adalimumab versus placebo achieved HiSCR.
V 12. tednu je statistično pomembno večji delež bolnikov, ki so prejemali adalimumab, dosegel klinični odziv (HiSCR) v primerjavi z bolniki, ki so prejemali placebo.
Serious infections were seen in clinical studies with concurrent use of anakinra and another TNFantagonist, etanercept, with no added clinical benefit compared to etanercept alone.
V kliničnih študijah s sočasno uporabo anakinre in etanercepta, drugega antagonista TNF, so opazili hude okužbe brez dodatnih kliničnih prednosti v primerjavi z etanerceptom samim.
Imraldi is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.
Zdravilo Imraldi je indicirano za zdravljenje hudega aktivnega ankilozirajočega spondilitisa pri odraslih, ki se na konvencionalno terapijo ne odzovejo ustrezno.
Very common Respiratory tract infections (including lower and upper respiratory tract infection, pneumonia, sinusitis, pharyngitis, nasopharyngitis and pneumonia herpes viral)
zelo pogosti okužbe respiratornega trakta (vključno z okužbo spodnjega in zgornjega respiratornega trakta, pljučnico, vnetjem sinusa, vnetjem sluznice žrela, vnetjem nosnega dela žrela in pljučnim virusnim herpesom)
Fatty areas are good for inserting the needle correctly.
Na območjih z več podkožne maščobe je laže pravilno vstaviti iglo.
If these medicines do not work well enough, patients will be given Imraldi to treat their polyarticular juvenile idiopathic arthritis or enthesitis-related arthritis.
Če ta zdravila ne delujejo dovolj dobro, bolniki za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa ali artritisa, povezanega z entezitisom, dobijo zdravilo Imraldi.
If these medicines do not work well enough, you will be given Imraldi to treat your rheumatoid arthritis.
Če ta zdravila ne delujejo dovolj dobro, boste za zdravljenje revmatoidnega artritisa dobili zdravilo Imraldi.
If your child has been told by doctor that he/she has an intolerance to some sugars, contact your doctor before taking this medicinal product.
Če je zdravnik vašemu otroku povedal, da ne prenaša nekaterih sladkorjev, se obrnite na zdravnika, preden bo vaš otrok vzel to zdravilo.
General handling: DO NOT dispose of any waste items until after the injection is completed.
2) Priprava odmerka zdravila Imraldi za injiciranje Splošno ravnanje: NE ZAVRZITE nobenega uporabljenega dela, dokler ne dokončate injiciranja.
• 80 mg at week 0 and 40 mg at week 2
• 80 mg v 0. tednu in 40 mg v 2. tednu
• Store your vial in the refrigerator, but do not freeze it.
• Vialo shranjujte v hladilniku, vendar ne sme zamrzniti.
Table 15 Efficacy Response in Placebo-Controlled Period for Study nr-axSpA II
Odziv učinkovitosti v s placebom kontroliranem obdobju študije nr-axSpA II Dvojno slepa
Maintenance of remission and response rates are presented in Table 24.
Vzdrževanje remisije in deleže odziva prikazuje preglednica 24.
Week 26 Week 52 p value for Standard Dose versus Low Dose comparison 2 Immunosuppressant therapy could only be discontinued at or after week 26 at the investigator's discretion if the subject met the clinical response criterion 3 Defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive post-Baseline visits
Zdravljenje z imunosupresivi je bilo lahko prekinjeno v 26. tednu ali po njem po raziskovalčevi diskreciji, če je bolnik izpolnjeval kriterije kliničnega odziva 3 Definiran kot zaprtje vseh fistul, ki so bile prisotne ob začetku študije na vsaj 2 zaporednih obiskih po začetku
Patients received an initial dose of 80 mg adalimumab followed by 40 mg every other week (starting one week after the initial dose) or placebo for 26 weeks followed by open-label adalimumab treatment for an additional 26 weeks.
Bolniki so prejeli začetni odmerek 80 mg adalimumaba, ki mu je sledil 40 mg odmerek vsak drugi teden (z začetkom en teden po začetnem odmerku), ali placebo naslednjih 26 tednov, čemur je sledilo odprto zdravljenje z adalimumabom dodatnih 26 tednov.
Excipients with known effects
Pomožne snovi z znanim učinkom:
Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (See Table 24).
Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali adalimumab, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 24).
c Ankylosing Spondylitis Disease Activity Score d Partial flare is defined as ASDAS ≥ 1.3 but < 2.1 at 2 consecutive visits.
Society b izhodišče je določeno kot izhodišče odprte faze, ko imajo bolniki aktivno bolezen c ocena bolezenske aktivnosti ankilozirajočega spondilitisa (Ankylosing Spondylitis Disease Activity Score) d Delni zagon bolezni je določen kot ASDAS ≥ 1,3 vendar < 2,1 pri dveh zaporednih obiskih.
Table 13 Efficacy Responses in Placebo-Controlled AS Study - Study I Reduction of Signs and Symptoms
Odzivi učinkovitosti v študiji pri ankilozirajočem spondilitisu, kontrolirani s placebomštudija I Zmanjšanje znakov in simptomov
• With your free hand, pick up the needle package with the yellow syringe connector facing down.
• S prosto roko primite pakiranje igle, in sicer tako, da rumeni konektor za brizgo gleda navzdol.
6 months 12 months ACR 50
12 mesecevACR 50
In an open-label extension study, for patients who dose escalated from 40 mg every other week to 40 mg weekly due to a PASI response below 50 %, 26.4 % (92/349) and 37.8 % (132/349) of patients achieved PASI 75 response at week 12 and 24, respectively.
V odprti podaljšani študiji je odziv PASI 75 v 12. tednu oziroma 24. tednu doseglo 26,4 % (92/349) oziroma 37,8 % (132/349) bolnikov, ki so jim zaradi odziva PASI pod 50 % odmerek povečali s 40 mg vsak drugi teden na 40 mg vsak teden.
If you are unsure, contact your doctor.
Če niste gotovi, se posvetujte z zdravnikom.
In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy, adalimumab monotherapy and adalimumab/methotrexate combination therapy, respectively.
V odprtem podaljšanju študije revmatoidnega artritisa V je bila povprečna sprememba celotne Sharpove ocene v 10. letu pri bolnikih, ki so jih na začetku randomizirali na monoterapijo z metotreksatom, monoterapijo z adalimumabom in kombinacijo adalimumaba/metotreksata, glede na izhodišče 10,8, 9,2 oz. 3,9.
• You will need a special container for waste, such as a sharps container or as instructed by your nurse, doctor or pharmacist.
• Potrebovali boste poseben vsebnik za odpadke, kot je vsebnik za odlaganje ostrih predmetov, ali kot vam bodo naročili sestra, zdravnik ali farmacevt.
At week 4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or Standard Dose maintenance regimens as shown in Table 19.
V 4. tednu so bili bolniki glede na njihovo telesno maso v tem času randomizirani v razmerju 1:1 bodisi v vzdrževalni režim z majhnim odmerkom ali vzdrževalni režim s standardnim odmerkom, kot kaže preglednica 19.
Imraldi is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.
Zdravilo Imraldi je indicirano za zdravljenje kroničnega, neinfekcijskega, anteriornega uveitisa pri pediatričnih bolnikih, starejših od 2 let, ki se niso ustrezno odzvali ali ne prenašajo konvencionalnega zdravljenja ali pri katerih konvencionalno zdravljenje ni primerno.
In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36 showed greater improvement (p <0.001) for adalimumab/methotrexate combination therapy versus methotrexate monotherapy and adalimumab monotherapy at week 52, which was maintained through week 104.
V študiji revmatoidnega artritisa V sta se indeks invalidnosti HAQ in telesna komponenta SF 36 ob kombinirani terapiji z adalimumabom in metotreksatom po 52 tednih izboljšala bolj (p < 0,001) kot ob monoterapiji z metotreksatom ali ob monoterapiji z adalimumabom; to se je ohranilo do 104. tedna.
The recommended dose of Imraldi for patients with ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and for patients with psoriatic arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection.
Priporočeni odmerek zdravila Imraldi pri bolnikih z ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za AS in pri bolnikih s psoriatičnim artritisom je 40 mg adalimumaba, apliciran v enkratni subkutani injekciji vsak drugi teden.
The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 patient-years among adalimumab-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control patients.
Delež (95-% interval zaupanja) nemelanomskih kožnih rakov je bil 8,8 (6,0; 13,0) na 1.000 bolnikov-let med bolniki, ki so dobivali adalimumab, in 3,2 (1,3; 7,6) na 1.000 bolnikov-let med kontrolnimi bolniki.
Table 26 Paediatric CD Study PCDAI Clinical Remission and Response
Študija Crohnove bolezni pri pediatričnih bolnikih PCDAI klinična remisija in odziv
Leukocytosis, thrombocytopenia Uncommon Idiopathic thrombocytopenic purpura Rare
anemija pogosti levkocitoza, trombocitopenija občasni idiopatska trombocitopenična purpura redki pancitopenija
• If you have an infection, including long-term or localised infection (for example, leg ulcer) consult your doctor before starting Imraldi.
• Če imate kakšno okužbo, vključno z dolgotrajno ali omejeno okužbo (npr. razjedo na nogi), se pred uporabo zdravila Imraldi posvetujte z zdravnikom.
• sensation of heart beating irregularly such as skipped beats;
• občutek neenakomernega bitja srca, kot je preskakovanje utripov;
• vaccinations
• cepljenja
• If your child has an infection, including long-term or localised infection (for example, leg ulcer) consult your doctor before starting Imraldi.
• Če ima vaš otrok kakšno okužbo, vključno z dolgotrajno ali omejeno okužbo (npr. razjedo na nogi), se pred uporabo zdravila Imraldi posvetujte z zdravnikom.
 4 pre-filled syringes, each with 1 alcohol pad  6 pre-filled syringes, each with 1 alcohol pad
 4 napolnjenih injekcijskih brizg, vsak z 1 alkoholnim zložencem  6 napolnjenih injekcijskih brizg, vsak z 1 alkoholnim zložencem
In study UC-II, among those treated with adalimumab who were in remission at week 8, 21/41 (51 %) were in remission at week 52.
V študiji UC-II je bilo 21/41 bolnikov (51 %), ki so bili zdravljeni z adalimumabom in so dosegli remisijo 8. teden, v remisiji
Patients who achieved sustained remission for at least 12 weeks (N=305) (ASDAS < 1.3 at Weeks 16, 20, 24, and 28) during the open-label period were then randomized to receive either continued treatment with adalimumab 40 mg eow (N=152) or placebo (N=153) for an additional 40 weeks in a double-blind, placebo-controlled period (total study duration 68 weeks).
Bolniki, ki so v odprti fazi dosegli trajno remisijo za vsaj 12 tednov (N = 305) (ASDAS < 1,3 v 16., 20., 24. in 28. tednu), so bili nato randomizirani tako, da so prejemali bodisi nadaljevalno zdravljenje z zdravilom adalimumab 40 mg vsak drugi teden (N = 152)
2 years.
2. teden.
In study nr-axSpA I, adalimumab 40 mg every other week was assessed in 185 patients in a randomised, 12 week double - blind, placebo - controlled study in patients with active nr-axSpA (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.4 for patients treated with adalimumab and 6.5 for those on placebo) who have had an inadequate response to or intolerance to ≥1 NSAIDs, or a contraindication for NSAIDs.
Uporabo 40 mg adalimumaba vsak drugi teden so proučili v randomizirani, 12 tednov trajajoči, dvojno slepi, s placebom kontrolirani študiji nr-axSpA I pri 185 bolnikih z aktivnim nr-axSpA I (srednja vrednost aktivnosti bolezni [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] je bila 6,4 pri bolnikih, zdravljenih z adalimumabom, in 6,5 pri bolnikih na placebu), ki so nezadostno reagirali na ali niso prenašali vsaj enega NSAID ali s kontraindikacijo za NSAID.
• vertigo (sensation of the room spinning);
• vrtoglavica (občutek, da se prostor vrti);
• If your child has mild heart failure and is being treated with Imraldi, his/her heart failure status must be closely monitored by your doctor.
• Če ima vaš otrok blago srčno popuščanje in se zdravi z zdravilom Imraldi, mora zdravnik natančno nadzorovati stanje njegovega srčnega popuščanja.
EU/1/17/1216/001 1 pre-filled syringe EU/1/17/1216/002 2 pre-filled syringes EU/1/17/1216/003 4 pre-filled syringes EU/1/17/1216/004 6 pre-filled syringes
EU/1/17/1216/001 1 napolnjena injekcijska brizga EU/1/17/1216/002 2 napolnjeni injekcijski brizgi EU/1/17/1216/003 4 napolnjene injekcijske brizge EU/1/17/1216/004 6 napolnjenih injekcijskih brizg
The recommended dose of Imraldi is an initial dose of 20 mg, followed by 20 mg one week later.
Priporočeni odmerek zdravila Imraldi je začetni odmerek 20 mg, ki mu sledi 20 mg en teden kasneje.
Imraldi is available in packs containing 1, 2, 4 or 6 pre-filled pen(s) containing a pre-filled syringe (type I glass) with a stainless steel needle, a rigid needle shield, a rubber plunger for patient use and 2, 2, 4 or 6 alcohol pads are enclosed in packs respectively.
Zdravilo Imraldi je na voljo v pakiranjih, ki vsebujejo 1, 2, 4 ali 6 napolnjenih injekcijskih brizg (iz stekla tipa I) z iglo iz nerjavnega jekla, rigidnim varovalom za iglo, batom iz gume, steblom bata, zaščitnim ohišjem in prirobnico za bolnikovo uporabo ter 2 ali 2, 4 oziroma 6 priloženih alkoholnih zložencev.
Age Group Number of patients at Baseline N (%) Minimum, median and maximum
Starostna skupina Izhodiščno število bolnikov N (%)
• There have been cases of cancers, other than lymphoma in patients with a specific type of lung disease called chronic obstructive pulmonary disease (COPD) treated with another TNFα blocker.
• Pri bolnikih s posebno boleznijo pljuč, t.i. kronično obstruktivno pljučno boleznijo (KOPB), zdravljenih z nekim drugim zaviralcem TNFα, so bili primeri rakov, ki niso bili limfomi.
• Make sure you know the proper amount (volume) needed for dosing.
• Preverite točen odmerek (volumen) zdravila za vašega otroka.
If you develop a fever that does not go away, or you bruise or bleed very easily or look very pale, call your doctor right away.
Če dobite zvišano telesno temperaturo, ki ne mine, ali če se vam zlahka pojavljajo podplutbe ali zlahka zakrvavite ali ste zelo bledi, se takoj posvetujte z zdravnikom.
• Choose a fatty area for injection:
• Za injiciranje izberite mesto z veliko podkožne maščobe:
DO NOT touch the area again before injecting.
Očiščenega mesta se do injiciranja ne dotikajte več.
Among those, 40 patients showed no progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less.
Med njimi 40 bolnikov ni pokazalo napredovanja strukturne prizadetosti, izražene s spremembo modificirane celotne Sharpove ocene 0,5 ali manj od začetka študije.
>32 weeks
32-tedenskega obdobjaa
6 months 12 months a RA study I at 24 weeks, RA study II at 26 weeks, and RA study III at 24 and 52 weeks b 40 mg adalimumab administered every other week c MTX = methotrexate
12 mesecev a Študija revmatoidnega artritisa I po 24 tednih, študija revmatoidnega artritisa II po 26 tednih in študija revmatoidnega artritisa III po 24 in 52 tednih b 40 mg adalimumaba, danega vsak drugi teden.
The recommended dose of Imraldi for adult patients with rheumatoid arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection.
Priporočeni odmerek zdravila Imraldi za odrasle bolnike z revmatoidnim artritisom je 40 mg adalimumaba vsak drugi teden v enkratnem odmerku v subkutani injekciji.
On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship was established between plasma concentrations and PedACR 50 response.
Na podlagi podatkov iz kliničnih preskušanj pri bolnikih z juvenilnim idiopatskim artritisom (JIA) (poliartikularnim idiopatskim artritisom (pJIA) in z artritisom, povezanim z entezitisom (ERA)) je bilo dokazano razmerje med izpostavljenostjo in odzivom med plazemskimi koncentracijami in PedACR
Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumab compared with placebo at week 56.
Z boleznijo povezanih hospitalizacij in operacij je bilo do 56. tedna med uporabo adalimumaba statistično značilno manj kot med uporabo placeba.
Following the administration of 0.8 mg/kg (up to a maximum of 40 mg) subcutaneously every other week to paediatric patients with chronic plaque psoriasis, the mean ± SD steady-state adalimumab trough concentration was approximately 7.4 ± 5.8 μg/ml (79% CV).
Po dajanju adalimumaba 0,8 mg/kg (do največ 40 mg) subkutano vsak drugi teden pediatričnim bolnikom s kronično psoriazo v plakih, je bila povprečna (±SD) najmanjša koncentracija adalimumaba v stanju dinamičnega ravnovesja približno 7,4 ± 5,8 µg/ml (79 % KV).
Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use of adalimumab.
Pri uporabi adalimumaba so poročali tudi o smrtnih in življenjsko ogrožajočih okužbah (vključno s sepso, oportunističnimi okužbami in TB), HBV reaktivaciji in različnih malignih obolenjih (vključno z levkemijo, limfomom in HSTCL).
Among those, 64 patients (79.0 %) had ACR 20 responses; 56 patients (69.1 %) had ACR 50 responses; and 43 patients (53.1 %) had ACR 70 responses.
(79,0 %) imelo odziv 20 po ACR; 56 bolnikov (69,1 %) je imelo odziv 50 po ACR; in 43 bolnikov (53,1 %) je imelo odziv 70 po ACR.
• cutaneous vasculitis (inflammation of blood vessels in the skin);
• kožni vaskulitis (vnetje krvnih žil v koži);
Hold the syringe on the graduated area and pull the syringe from its package.
Primite brizgo na delu z merilom (graduiranem delu) in jo vzemite iz ovojnine.
Be sure to remove the vial adapter with the vial from the syringe.
Poskrbite, da boste adapter za vialo in vialo sneli z brizge.
Discontinuation of Immunomodulators2
Prenehanje z imunomodulatorji2
The recommended dose of Imraldi for patients with Crohn's disease from 6 to 17 years of age is based on body weight (Table 4).
Priporočeni odmerek zdravila Imraldi pri bolnikih s Crohnovo boleznijo, starih od 6 do 17 let, temelji na telesni masi (preglednica 4).
• If you are about to have surgery or dental procedures tell your doctor that you are taking Imraldi.
• Če boste imeli kirurški poseg ali poseg na zobeh, povejte zdravniku, da jemljete zdravilo Imraldi.
Imraldi is used to treat Crohn's disease in adults and children aged 6 to 17 years.
Zdravilo Imraldi se uporablja za zdravljenje Crohnove bolezni pri odraslih in otrocih, starih 6 do